from OP's article: > In the developing world, where healthcare resources, infrastructure and economics are so different, we have entered into agreements with g

from OP's article: > In the developing world, where healthcare resources, infrastructure and economics are so different, we have entered into agreements with generic manufacturers to deliver treatment at a substantially lower cost. I assume this means that: 1. Remdesvir is not that hard to manufacture. 2. Gilead will license the drug to 3rd party factories, so no need to manufacture them in the US.